The
Food and Drug Administration granted Orphan Drug designation to Prana
Biotechnolgy Ltd.'s (Nasdaq: PRAN) Huntington Disease treatment PBT2 lifting the stock price 37 cents to $2.51.
Prana receives Orphan Drug designation
September 05, 2014 at 14:38 PM EDT